TL;DR
- 1.Roughly 30% of people carry the TNF-alpha -308 A allele. It doesn't just raise inflammation. It makes inflammation harder to turn off, which is a different problem entirely.
- 2.A 2025 study in Cells found TNF-alpha A-allele carriers had 75% persistent post-injury dysfunction vs. 17% in non-carriers. Same injury, same protocol, very different outcomes.
- 3.Three SNPs cover most of the genetic variation in healing response: TNF-alpha rs1800629, IL-6 rs1800795, and IL-10 rs1800896. Each maps to a different peptide mechanism.
- 4.BPC-157 suppresses NF-kB by roughly 55% and cuts tissue IL-6 by about 62% in animal models. For TNF-alpha and IL-6 high-producers, that's the mechanism they need most.
- 5.KPV and Thymosin Alpha-1 work primarily through the IL-10 pathway. If you're a low-producer at rs1800896, those peptides compensate for the deficit your genes create.
A 2025 clinical study published in Cells tracked rehabilitation outcomes in patients who had suffered traumatic brain injuries. Every patient received the same care. The TNF-alpha -308 A-allele carriers had a 75% rate of persistent post-traumatic confusion at the end of rehabilitation. The non-carriers: 17%. Same injury severity. Same treatment protocol. The difference was a single nucleotide.
Persistent recovery dysfunction in TNF-alpha A-allele carriers versus non-carriers after identical treatment, from the 2025 Cells study on cytokine genetics and rehabilitation outcomes (n=28).
This is the statistic most peptide content refuses to discuss. The biohacking community frames non-response as a protocol problem: wrong dose, wrong timing, low-quality compound. Genetics content covers these SNPs in the context of diet and supplements. Nobody connects the two. If your TNF-alpha, IL-6, or IL-10 genotype puts you in the high-inflammation category, the peptide you pick and the one you should pick can be completely different things.
Here is what the research actually shows, and what it means for choosing a healing protocol.
Think of inflammation as a thermostat, not a dial. Most people assume high inflammation means the dial is turned up too high. The research shows a different problem: for many people, the thermostat itself is broken. The heat comes on normally after injury. It just never gets the signal to turn back off. That failure to resolve -- not the initial spike -- is what drives slow healing, chronic soreness, and peptide non-response.
Why Healing Peptides Produce Different Results in Different People
If you have used BPC-157 or TB-500 and felt nothing, the standard answer from online forums is that your product was underdosed, your administration was off, or you need to run it longer. Those factors matter. But they don't explain why two people doing the same 8-week sub-Q protocol on verified compounds can have completely opposite experiences.
The explanation that the peptide community almost never discusses is inflammation genotype. Your baseline inflammatory tone, how strongly your immune system fires in response to injury or stress, and how quickly it resolves afterward, is substantially heritable. Three gene variants cover most of the genetic variance in this response: TNF-alpha rs1800629, IL-6 rs1800795, and IL-10 rs1800896.
Each of these variants changes a different phase of the inflammatory process. TNF-alpha rs1800629 affects the initial pro-inflammatory signal. IL-6 rs1800795 affects the sustained acute-phase response. IL-10 rs1800896 affects the resolution signal, the biological instruction to stop. Together, they determine the inflammatory environment that healing peptides have to work inside.
For a full picture of why non-response to BPC-157 specifically has more than one cause, our article on why BPC-157 healed tendons in 8 weeks but not everyone responds the same covers the peptide side. The genetics side is what this article addresses.
The TNF-Alpha -308 Variant: When Inflammation Refuses to Turn Off
TNF-alpha (tumor necrosis factor alpha) is the cytokine that kicks off the inflammatory cascade. When tissue is damaged, TNF-alpha fires first. It recruits immune cells, signals pain receptors, and initiates the repair sequence. You need it. The problem is the -308 G/A polymorphism at rs1800629.
The A allele doesn't just raise TNF-alpha levels. It changes how the gene responds to inflammatory triggers. Carriers of the A allele have upregulated TNF-alpha promoter activity, meaning the same tissue insult produces a disproportionately strong TNF response, and that response takes longer to resolve.
Approximate prevalence of the TNF-alpha -308 A allele among people of European descent, making it one of the most common inflammation risk variants in genetic databases.
The 2025 study in Cells (Pinca et al., PMC12293546) documented this in rehabilitation outcomes after traumatic brain injury. The A-allele genotype correlated with worse Barthel score recovery, worse mobility scores, and a dramatically higher rate of persistent post-traumatic confusional state. The counterintuitive finding was the mechanism: it was not peak inflammation that predicted worse outcomes. It was clearance kinetics. A-allele carriers had inflammation that lingered past the window where it was useful and into the window where it was actively harmful.
"TNF-alpha -308 GA heterozygotes showed worse Barthel and mobility recovery and higher rates of post-traumatic confusional state. IL-6 -174 GG and IL-6R 1073 AA genotypes also independently correlated with worse GOSE scores (p = 0.01 to 0.02), suggesting that pro-inflammatory cytokine gene variants specifically impair the resolution phase of neuroinflammation."
Cells, July 2025 (Pinca et al., PMC12293546)
This distinction matters enormously for peptide selection. Most anti-inflammatory peptides are designed to blunt the initial inflammatory response. BPC-157, specifically, suppresses NF-kB nuclear translocation (the molecular switch that sustains TNF-alpha and IL-6 signaling) by roughly 55% and reduces tissue IL-6 by approximately 62% in animal models, according to the 2025 narrative review in Current Reviews in Musculoskeletal Medicine (PMC12446177). For TNF-alpha A-allele carriers who have a sustained NF-kB activation problem, BPC-157's primary mechanism is a direct match.
What High TNF Actually Does to Your Healing Timeline
The conventional framing is: more TNF-alpha means more inflammation means slower healing. The reality is more specific. Elevated TNF-alpha from the A allele does three things that directly interfere with tissue repair.
First, it prolongs M1 macrophage dominance. M1 macrophages are the inflammatory demolition crew: they clear debris and signal damage. The repair phase requires M2 macrophages to take over. High TNF-alpha delays that shift. Without M2 polarization, you get inflammation without the resolution that actually builds new tissue.
Second, it elevates systemic NF-kB signaling, which keeps the entire inflammatory cascade active even after the immediate stimulus is gone. This is the "stuck thermostat" problem.
Third, it sensitizes pain receptors during the resolution phase, which is why A-allele carriers often report ongoing soreness and stiffness well past when tissue-level healing should be complete. The soreness is real. It's driven by sustained cytokine signaling, not ongoing structural damage.
IL-6 Genotype: The Variant That Keeps Recovery Running Hot After Exercise
If TNF-alpha rs1800629 is the ignition switch for pro-inflammatory signaling, IL-6 rs1800795 is the accelerator. IL-6 is the cytokine that sustains the acute-phase response, recruits additional immune cells, and signals the liver to produce C-reactive protein (CRP). You want IL-6 to spike after injury. You want it to come back down.
The rs1800795 GG genotype at the -174 position raises baseline and injury-triggered IL-6 output. The 2025 study in Cells (PMC12293546) found that IL-6-174 GG genotype carriers independently showed worse Glasgow Outcome Scale Extended scores after traumatic brain injury (p=0.02). When IL-6 stays elevated past the acute injury window, it extends the inflammatory phase and delays the tissue remodeling that produces actual recovery.
For athletes and active people, IL-6 GG genotype translates directly to longer recovery windows. Exercise-induced muscle damage produces an IL-6 spike. GG carriers sustain that IL-6 elevation for longer after comparable training loads, the difference between feeling recovered and carrying residual soreness and systemic fatigue well past when GC or CC carriers have cleared it.
A 2021 meta-analysis in Inflammation Research (PMC8572816) pooled 21 European studies and confirmed that GG carriers have significantly higher circulating IL-6 compared to C-allele carriers. That finding has a direct parallel for peptide response: if your IL-6 system sustains elevation longer, you need a peptide that specifically targets the IL-6 pathway, not one that works only on the initial acute signal.
IL-10: The Genetic Off Switch Your Immune System May Be Missing
IL-10 is the anti-inflammatory cytokine that resolves the cascade. Once damage is repaired, IL-10 signals macrophages to shift from M1 to M2, tells T cells to stand down, and instructs the liver to end acute-phase production. Without adequate IL-10, the inflammation response has no clean exit.
The rs1800896 -1082 A/G polymorphism directly affects IL-10 promoter activity. The G allele produces higher IL-10 transcription. The A allele produces less. AA carriers are functionally "low producers" of the cytokine that tells inflammation to stop. In bioRxiv preprint data on wound healing genetics, endogenous IL-10 levels directly predicted macrophage polarization outcomes and scar quality: lower IL-10 correlated with prolonged M1 dominance and more fibrotic healing.
This is the variant that makes people describe their healing as "incomplete." The injury closes. The tissue looks healed. But there is residual stiffness, reduced range of motion, and a tendency for the area to re-inflame with less provocation than before. That pattern fits the biology of impaired IL-10 resolution almost exactly.
BPC-157 and the NF-kB / IL-6 pathway
BPC-157 suppresses NF-kB nuclear translocation and reduces tissue IL-6 by approximately 62% in preclinical models. Its primary mechanism targets the TNF-alpha and IL-6 arms of the inflammatory cascade, making it a strong fit for rs1800629 A-allele carriers and rs1800795 GG carriers who have elevated pro-inflammatory signaling. It shifts macrophages toward M2 polarization, which is the mechanism that drives actual tissue rebuilding.
KPV and the IL-10 / NF-kB resolution pathway
KPV is a tripeptide derived from alpha-MSH that suppresses NF-kB and upregulates IL-10. Its Phase IIb trial in ulcerative colitis found 67% endoscopic remission versus 23% placebo at 12 weeks. For rs1800896 A-allele carriers who are low IL-10 producers, KPV directly compensates for the anti-inflammatory deficit. Thymosin Alpha-1 works through a similar resolution mechanism via T-cell recalibration and IL-10 upregulation.
Which Healing Peptides Match Which Inflammation Genotype
The research does not yet include human trials testing peptides specifically against these SNP combinations. What exists is two independent streams of evidence: the genotype-to-inflammation mapping, and the peptide-to-mechanism mapping. Where they overlap, the matches are logical and specific.
| Genotype | Variant | What it does to healing | Best peptide match | Mechanism overlap |
|---|---|---|---|---|
| TNF-alpha GA or AA | rs1800629 | NF-kB stays active longer; M1 macrophage dominance; slower resolution | BPC-157, TB-500 | BPC-157 suppresses NF-kB ~55%; TB-500 promotes actin remodeling and tissue reconstruction independent of TNF signaling |
| IL-6 GG | rs1800795 | Higher and more prolonged IL-6; longer recovery; higher CRP baseline | BPC-157, GHK-Cu | BPC-157 reduces IL-6 ~62% in tissue models; GHK-Cu modulates gene expression to reduce IL-6 and IL-1 signaling |
| IL-10 AA | rs1800896 | Low IL-10 production; incomplete resolution; fibrotic healing pattern | KPV, Thymosin Alpha-1 | KPV upregulates IL-10 directly; Thymosin Alpha-1 recalibrates T-cell balance toward the Th2/regulatory axis that promotes IL-10 production |
| TNF-alpha GA + IL-6 GG | Both pro-inflammatory | Amplified acute response and prolonged sustain; the "stuck accelerator" pattern | BPC-157 primary + TB-500 secondary | Layered NF-kB suppression and tissue remodeling; BPC-157 handles the cytokine environment, TB-500 drives structural repair |
| IL-10 AA + TNF-alpha GA | Pro-inflammatory with no off switch | High TNF plus low resolution capacity; most severe non-response profile | BPC-157 + KPV combination | BPC-157 suppresses pro-inflammatory signals; KPV compensates for the IL-10 deficit; together they address both phases |
One clarification worth making: none of these peptides require a specific genotype to produce benefit. BPC-157 heals tendons in people with no inflammation gene variants. The table above identifies where the match is strongest, not where it is exclusive.
The Correction Most Articles Get Wrong About High-Inflammation Genotypes
The dominant narrative in genetics content is that the TNF-alpha A allele makes you a "high inflammation" person. The 2025 Cells TBI data complicates that. A-allele carriers did not have universally worse inflammation. They had inflammation that lingered into the resolution phase, when GG carriers had already cleared it.
This matters for peptide selection because "anti-inflammatory" peptides vary considerably in what part of the inflammatory process they act on. Peptides that blunt the initial spike (like certain anti-nociceptive compounds) would be the wrong choice for A-allele carriers whose initial spike is normal. Peptides that accelerate clearance and resolution are the right choice.
BPC-157's NF-kB mechanism operates specifically in the sustained signaling phase, not the initial acute spike. That is why it is a particularly strong match for rs1800629 A-allele carriers. It targets the exact phase that is dysregulated in that genotype.
For a broader look at how immune genetics shape peptide protocols, our guide on Thymosin Alpha-1 and what 11,000 human subjects actually showed covers the immune-modulation side in depth. The APOE4 genetics article on neuroprotective peptides for the Alzheimer's risk gene is also relevant context for how specific genotypes change which peptides are prioritized.
You can see BPC-157's full mechanism profile, evidence summary, and genetic match scoring at the BPC-157 peptide page.
How to Find Out Your Inflammation Genotype
Standard 23andMe and AncestryDNA tests do cover rs1800629 (TNF-alpha -308), rs1800795 (IL-6 -174), and rs1800896 (IL-10 -1082). If you have raw genetic data from either service, these variants are present in the file.
Reading them yourself involves looking up each rsID in your raw data, then interpreting the allele calls against the published literature. That process is error-prone and context-free. Knowing you are GA at rs1800629 tells you the genotype. It does not tell you which peptides match, how to order them by priority, or how your other genetic variants interact.
Our panel interprets inflammation genotype in the context of your full genetic profile and maps each variant to the peptides with the strongest mechanistic case. For what DNA tests can and cannot tell you about peptide response, our guide on what your 23andMe data can actually tell you about peptides covers the practical limits and possibilities in detail.
The verdict: Your inflammation genotype is not a minor modifier of healing peptide response. For the roughly 30% carrying the TNF-alpha A allele, the IL-6 GG pattern, or the low-IL-10 AA variant, it is the primary determinant of whether a standard healing protocol works at all.
The 2025 Cells study showed 75% persistent dysfunction in A-allele carriers versus 17% in non-carriers receiving identical care. That gap is not explained by dose or protocol. It is explained by the inflammatory environment the peptides have to work inside. Matching BPC-157 to the TNF/IL-6 pathway problem, or KPV to the IL-10 deficit, is not optimization. For certain genotypes, it is the difference between a response and no response at all.
Ready to see your inflammation genotype and how it ranks the healing peptides? Upload your raw DNA file for an instant match score, or order a kit if you do not have genetic data yet.
Your DNA shapes how you respond to every peptide in this report.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is the TNF-alpha inflammation genotype?
TNF-alpha rs1800629 is a genetic variant in the promoter region of the tumor necrosis factor alpha gene. The G allele is the common form. The A allele raises TNF-alpha production in response to inflammatory triggers. Carriers of the A allele (GA or AA) don't just produce more inflammation: they have inflammation that takes longer to resolve. Approximately 30% of people of European descent carry at least one A allele.
How does my inflammation genotype affect how well healing peptides work?
Your inflammation genotype determines the cytokine environment that healing peptides operate inside. If your TNF-alpha stays elevated past the point where tissue repair begins, peptides that work through the resolution phase are more effective than those that address the initial spike. A 2025 study in Cells found that TNF-alpha A-allele carriers had 75% persistent post-injury dysfunction versus 17% in non-carriers given the same treatment, illustrating how dramatically genotype shapes outcomes in identical protocols.
Can BPC-157 help if I have a high-inflammation genotype?
Yes, and it may be especially relevant. BPC-157 suppresses NF-kB nuclear translocation by roughly 55% and reduces tissue IL-6 by approximately 62% in preclinical models. Both TNF-alpha A-allele carriers and IL-6 GG carriers have elevated NF-kB and IL-6 signaling during the resolution phase. BPC-157's primary mechanism targets that exact dysfunction. The 2025 systematic review in Orthopaedic Journal of Sports Medicine confirmed consistent healing improvement across 36 studies, with the biological case for high-inflammation genotypes being particularly strong.
What is the difference between being a 'hot' versus 'cold' healer?
A 'hot' healer has inflammation genotype variants that amplify the pro-inflammatory signal: TNF-alpha A allele, IL-6 C allele, or both. Their inflammation spikes strongly and resolves slowly. A 'cold' healer may have adequate IL-10 production and lower baseline inflammation, meaning healing peptides operate in a cleaner environment. The distinction matters because the same peptide dose and protocol produces very different results depending on which direction your genetics push. Neither is strictly better: hot healers may clear some infections more aggressively, but they pay a recovery cost.
How do I know if I have the TNF-alpha A allele?
If you have raw genetic data from 23andMe or AncestryDNA, search your file for rs1800629. The result will show two letters representing your two alleles: GG (non-carrier), GA (one A allele, carrier), or AA (two A alleles, homozygous carrier). GA is the most common carrier state. Alternatively, our PeptidesDNA report reads this variant from your raw data and presents it alongside its clinical relevance and peptide implications, without requiring you to look up rsIDs manually.
Does IL-6 genotype affect my recovery after exercise?
Yes, meaningfully. IL-6 rs1800795 GG carriers produce more IL-6 in response to exercise-induced muscle damage than GC or CC carriers. IL-6 drives the post-exercise inflammatory response and correlates with perceived soreness and fatigue. GG carriers typically show longer IL-6 elevation windows after training, which translates to slower subjective recovery. A 2021 meta-analysis in Inflammation Research confirmed that GG homozygotes have significantly higher circulating IL-6. Peptides that reduce IL-6 signaling, particularly BPC-157 and GHK-Cu, are especially relevant for GG carriers who find standard recovery protocols don't fully resolve soreness before the next session.
What is the best peptide for someone with high-inflammation genetics?
It depends on which variant is driving the problem. For TNF-alpha A-allele and IL-6 GG carriers, BPC-157 is the strongest match because it targets NF-kB and IL-6 signaling directly. For IL-10 AA carriers who lack the anti-inflammatory off switch, KPV and Thymosin Alpha-1 are better fits because they upregulate IL-10 and drive the resolution phase. For people carrying both pro-inflammatory variants and low IL-10, a combination protocol targeting both phases is often warranted. A DNA-based report can map your specific variant combination to a prioritized peptide ranking.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.